Saturday 17 October 2026
Export DHR’s income statement to Excel — free account
Danaher Corporation
DHR Healthcare Diagnostics & Research
Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024. In the quarter to June 2026, revenue grew 5.54%, EPS grew 59.7%, free cash flow grew 15.6% and total debt rose 49.2%, each against the same quarter a year earlier. Member of the S&P 500.
228.97
2.53
−1.09%
Follow DHR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
33.71 | 36.53 | 45.15 | 40.63 |
+8 more quarters Free account |
P/S ratio |
5.35 | 5.42 | 6.64 | 5.81 | |
P/FCF ratio |
24.48 | 25.24 | 30.82 | 28.02 | |
P/Operating CF |
87.58 | 101.53 | 77.07 | 84.78 | |
P/B ratio |
2.55 | 2.53 | 3.11 | 2.76 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
6.18 | 5.90 | 7.20 | 6.44 | |
EV/EBITDA |
20.14 | 20.17 | 24.79 | 22.21 | |
EV/Operating CF |
23.38 | 22.69 | 27.58 | 24.72 | |
EV/FCF |
28.26 | 27.47 | 33.43 | 31.07 | |
Quick Ratio |
1.03 | 1.28 | 1.25 | 0.84 | |
Current Ratio |
1.65 | 1.87 | 1.87 | 1.52 | |
Net Debt/EBITDA |
11.35 | 6.02 | 6.49 | 8.62 | |
Debt/Assets |
27.23% | 21.02% | 22.06% | 21.07% | |
Debt/Equity |
0.48 | 0.33 | 0.35 | 0.33 | |
Asset Turnover |
0.29 | 0.30 | 0.31 | 0.30 | |
Operating CF/Net income |
1.76 | 1.28 | 1.77 | 1.83 | |
Capex/Depreciation |
(0.38) | (0.38) | (0.56) | (0.47) | |
Interest Coverage |
10.53 | 21.33 | 27.31 | 17.22 | |
Research and Development Expense of Revenue |
6.58% | 6.50% | 6.41% | 6.24% | |
Selling, General and Administrative Expense of Revenue |
33.07% | 31.26% | 29.63% | 32.89% | |
Intangible Assets out of Total Assets |
0.74 | 0.72 | 0.73 | 0.76 | |
Share Based Compensation of Revenue |
1.48% | 0.97% | 0.92% | 1.37% | |
Graham Net Nets |
(0.20) | (0.12) | (0.11) | (0.14) | |
Graham Number |
97.36 | 93.47 | 91.70 | 88.83 | |
Earnings Yield |
2.97% | 2.74% | 2.21% | 2.46% | |
Free Cash Flow Yield |
4.09% | 3.96% | 3.24% | 3.57% | |
Revenue per Share |
8.88 | 8.41 | 9.59 | 8.52 | |
Operating CF per Share |
2.18 | 1.87 | 2.97 | 2.34 | |
Capex per Share |
(0.38) | (0.33) | (0.49) | (0.41) | |
Free Cash Flow per Share |
1.79 | 1.53 | 2.48 | 1.93 | |
Cash per Share |
6.16 | 8.05 | 6.48 | 2.15 | |
Shareholders Equity per Share |
74.57 | 74.81 | 73.72 | 71.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
74.57 | 74.81 | 73.72 | 71.87 | |
Free Cash Flow |
1,265.00 | 1,085.00 | 1,769.00 | 1,370.00 | |
Working Capital |
5,276.00 | 6,475.00 | 5,949.00 | 3,282.00 | |
Capital Expenditures |
(269.00) | (237.00) | (348.00) | (292.00) | |
Net Current Asset Value |
(26,394.00) | (16,652.00) | (18,167.00) | (19,211.00) | |
EV/EBIT |
30.26 | 30.69 | 37.73 | 33.86 | |
Capex to Sales |
0.04 | 0.04 | 0.05 | 0.05 | |
Price to Operating Income |
26.20 | 28.20 | 34.79 | 30.54 | |
| Other line items | |||||
Average Receivables |
3,764.50 | 3,662.50 | 3,725.00 | 3,631.00 | |
Average Payables |
1,773.50 | 1,756.00 | 1,798.50 | 1,647.00 | |
Average Inventory |
2,974.50 | 2,570.00 | 2,409.50 | 2,676.00 | |
Average Assets |
86,993.50 | 81,330.00 | 80,503.00 | 80,256.00 | |
Average Common Equity |
52,467.00 | 51,907.00 | 51,045.50 | 51,192.50 |
Columns are period end dates